|
|
|
| Disease burden of prostate cancer among residents at ages of 60 years and older in Zhangjiagang City from 2006 to 2022 |
| QIN Minye1, QIU Jing1, WANG Xunzhi1, ZHAO Lixia1, LU Yan2
|
1. Department of Chronic Disease Control and Prevention, Zhangjiagang Center for Disease Control and Prevention, Zhangjiagang, Jiangsu 215600, China;
2. Suzhou Center for Disease Control and Prevention, Suzhou, Jiangsu 215000, China |
|
|
|
|
Abstract Objective To investigate the trends in incidence, mortality and disease burden of prostate cancer among residents at ages of 60 years and older in Zhangjiagang City, Jiangsu Province from 2006 to 2022, so as to provide insights into improvements in the prostate cancer control strategy. Methods The incidence and mortality of prostate cancer among residents at ages of 60 years and older in Zhangjiagang City from 2006 to 2022 were collected from the Chronic Diseases Monitoring and Management System in the National Health Information Platform of Zhangjiagang City, and the crude incidence and mortality of prostate cancer were calculated and standardized to data from the sixth national population census in China in 2010. Based on the disease burden of prostate cancer captured from the 2019 Global Burden of Disease Study datasets, the years of life lost due to premature death (YLL) and years of life lived with disability (YLD) and disability-adjusted life years (DALY) due to prostate cancer were measured, and trends in incidence, mortality and disease burden of prostate cancer were analyzed using average annual percent change (AAPC). Results The crude incidence, standardized incidence, crude mortality, standardized mortality, crude DALY rate and standardized DALY rate of prostate cancer were 89.85/105, 83.87/105, 32.31/105, 25.45/105, 546.39/105 and 483.50/105 among residents at ages of 60 years and older in Zhangjiagang City from 2006 to 2022, which all appeared a tendency towards a rise (AAPC=5.346%, 4.219%, 6.648%, 3.697%, 4.198% and 2.200%, all P<0.05). The crude incidence, mortality and DALY rate of prostate cancer all appeared a tendency towards a rise with age (all P<0.05), with a tendency towards a rise seen for the crude incidence of prostate cancer among residents at ages of 60 to 64 years, 65 to 69 years and 70 to 74 years (AAPC=4.888%, 8.086% and 3.005%, all P<0.05), and a tendency towards a rise for the crude mortality and DALY rate among residents at ages of 80 years and older (AAPC=10.243% and 9.693%, both P<0.05). Conclusion The incidence and mortality of prostate cancer showed a tendency towards a rise among residents at ages of 60 years and older in Zhangjiagang City from 2006 to 2022, and the disease burden due to prostate cancer continued to increase, with a more remarkable increasing tendency seen for the incidence of prostate cancer among residents at ages of 60 to 74 years and for the mortality among residents at ages of 80 years and older.
|
|
Received: 10 August 2023
Revised: 21 October 2023
Published: 15 December 2023
|
|
|
|
|
|
［1］ SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin,2021,71(3):209-249.
[2] 闵淑慧,胡依,郭芮绮,等. 1990—2019年中国前列腺癌疾病负担分析及趋势预测[J].中国肿瘤,2023,32(3):171-177.
[3] 周孟孟,徐文超,俞浩,等. 1990—2019年江苏省男性前列腺癌疾病负担分析[J].实用肿瘤杂志,2023,37(1):1-5.
[4] 国家癌症中心.中国肿瘤登记工作指导手册(2016)[M]. 北京:人民卫生出版社,2016.
[5] 文煜,武振宇.疾病负担评价指标的实证分析——以伤残调整寿命年为例[J].卫生职业教育,2023,41(7):156-160.
[6] VOS T,LIM S S,ABBAFATI C,et al.Global burden of 369 diseases and injuries in 204 countries and territories,1990-2019: a systematic analysis for the Global Burden of Disease[J]. Lancet,2020,396(10258):1204-1222.
[7] 王临池,陆艳,黄春妍,等.2006—2020年苏州市前列腺癌死亡时空流行状况分析[J].中国初级卫生保健,2022,36(2):49-51.
[8] 刘硕,王硕,李慧超,等. 2000—2017年北京市前列腺癌发病和死亡流行趋势及发病年龄变化特征分析[J]. 中国肿瘤,2021,30(7):495-505.
[9] 王永,应焱燕,陈洁平,等. 2002—2022年宁波市恶性肿瘤死亡趋势分析[J]. 预防医学,2023,35(6):496-500.
[10] 张洁,费方荣,胡如英,等. 浙江省慢性病主要危险因素的归因疾病负担研究[J].预防医学,2022,34(6):541-546.
[11] 钱晓伟. 前列腺特异性抗原在老年前列腺疾病诊断中的应用研究[J]. 系统医学,2021,6(6):104-106.
[12] 贾铭,彭菊意,刘星宇,等. 心血管代谢性共病危险因素的Meta分析[J]. 预防医学,2023,35(9):790-795.
[13] 朱洪挺,胡云卿,李辉章,等. 2010—2014年浙江省肿瘤登记地区前列腺癌发病与死亡分析[J].中国肿瘤,2019,28(2):110-114. |
|
|
|
